Nearly 90% of the first-line biologics that patients with RA receive are anti-TNF therapy, and research has found that the majority will fail to satisfy the ACR50 criteria, which is a 50% or greater improvement in disease activity,…
Nearly 90% of the first-line biologics that patients with RA receive are anti-TNF therapy, and research has found that the majority will fail to satisfy the ACR50 criteria, which is a 50% or greater improvement in disease activity,…
Nearly 90% of the first-line biologics that patients with RA receive are anti-TNF therapy, and research has found that the majority will fail to satisfy the ACR50 criteria, which is a 50% or greater improvement in disease activity,…
Posted 10 September 2020 | By
The FDA granted breakthrough therapy designation to BeyondSpring’s first-in-class agent plinabulin for the chemotherapy-induced neutropenia (CIN) indication, according to a BeyondSpring press release.
Data for the full PROTECTIVE-2 phase 3 study is expected for the fourth quarter of 2020…
A homologous recombination deficiency (HRD) assay testing for impaired double-strand DNA break repair did not predict pathologic response to preoperative chemotherapy in a randomized trial of women with early-stage triple-negative breast cancer (TNBC) and no known BRCA…
Researchers developed a new class of medical instruments equipped with an advanced soft electronics system that could dramatically improve the diagnoses and treatments…
SIOUX FALLS — Avera announced it will participate in three Phase 2 and 3 clinical studies evaluating whether a combination of two lab-made antibodies can not only treat, but prevent SARS-CoV-2, the virus that causes COVID-19.
The clinical studies…
